As­traZeneca ex­pects US vac­cine da­ta ‘soon’ — with 50M dos­es ready by the end of April

As­traZeneca said it’s ready­ing the re­lease of da­ta from its US-based Phase III tri­al, which has more than 32,000 par­tic­i­pants, for its up­com­ing emer­gency use au­tho­riza­tion ap­pli­ca­tion.

“We ex­pect da­ta from our US Phase III tri­al to be avail­able soon, in the com­ing weeks, and we plan to file for emer­gency use au­tho­riza­tion short­ly there­after,” a com­pa­ny spokesper­son said via email.

A snap de­ci­sion on the vac­cine would put the US months be­hind the EU in au­tho­riz­ing it, but re­cent con­cerns about blood clots pushed Nor­way, Den­mark and Ice­land to halt the vac­cine’s use. The Eu­ro­pean Med­i­cines Agency, how­ev­er, not­ed, “As of 9 March 2021, 22 cas­es of throm­boem­bol­ic events had been re­port­ed among the 3 mil­lion peo­ple vac­ci­nat­ed with COVID-19 Vac­cine As­traZeneca in the Eu­ro­pean Eco­nom­ic Area.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.